FDA Committee Weighs Peptides for Weight Loss and Healing — RFK Jr. Backs Access, Reviewers Push Back

Executive Briefing

• Convenes FDA Pharmacy Compounding Advisory Committee July 23-24 to evaluate seven unapproved peptide substances for potential prescription use
• Covers peptides targeting obesity, wound healing, opioid withdrawal, insomnia, and neurological conditions across multiple delivery forms
• Reveals tension between RFK Jr.'s support for peptide access and FDA reviewers citing insufficient human clinical trial data
• Reports real-world adverse event rates below 0.1% across tens of millions of doses from 2014–2023, per testifying urologist Dr. Alex Tatem
• Requires additional FDA rulemaking after any committee recommendation before substances can be added to legal compounding list